This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Lymphocyte function antigen-1 [LFA-1] defect / Leukocyte adhesion deficiency type 1, LAD-1림프구기능항원-1결손 (백혈구접착결핍증 1형)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D84.0 (Lymphocyte function antigen-1 defect) | OMIM: #116920 (LAD1, ITGB2) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsLeukocyte adhesion deficiency type 1 (LAD-1), LFA-1 deficiency, CD18 deficiency, CD11/CD18 deficiency, Mac-1 deficiency, Leukocyte adhesion deficiency type I
C. Adult onsetLikelihood of first onset in adulthood very low — the severe form presents in the neonatal period to infancy with delayed umbilical cord separation and recurrent bacterial infections; the mild form with partial deficiency (CD18 expression 1~30%) is sometimes first diagnosed in childhood to adolescence, but first presentation in adulthood is extremely rare.
1. HistoryLate 1970s reports of children with severe recurrent infections and neutrophilia → 1980 Anderson, Springer et al. identified a deficiency of leukocyte surface glycoproteins → 1987 cloning of the ITGB2 gene → the name LAD-1 established → 2024 successful gene therapy clinical trial.
2. CausesPathogenic variants of the ITGB2 gene on chromosome 21 (21q22.3) → CD18 (β2 integrin) deficiency or loss of function → reduced expression of all LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18), and p150,95 (CD11c/CD18) complexes → inability of neutrophils to adhere to and migrate through the vessel wall.
3. GeneticsAutosomal recessive (OMIM #116920). More than 200 ITGB2 variants reported, including point mutations, frameshifts, and splicing variants. Classified by CD18 expression level as severe (<1%), moderate (1~10%), or mild (11~30%). Parents are asymptomatic heterozygous carriers.
4. General epidemiologyWorldwide prevalence about 1/10 million; fewer than about 400 cases reported worldwide. Males and females equally. Higher frequency in populations with high rates of consanguineous marriage. Specific large-scale statistics in Korea not established, but a few included among registered patients with rare immunodeficiencies.
5. PathophysiologyITGB2 variants → CD18 protein deficiency → loss of cell-surface expression of β2 integrin complexes (LFA-1, Mac-1, p150,95) → inability of neutrophils to roll on, adhere to, and transmigrate across the vascular endothelium → failure of neutrophil accumulation at sites of inflammation → sterile abscesses accompanied by blood neutrophilia.
6. SymptomsDelayed umbilical cord separation in the neonatal period (>28 days), omphalitis; recurrent bacterial and fungal infections (skin, lungs, gastrointestinal tract, oral cavity); delayed wound healing; periodontitis; in the severe form, risk of death mostly within the first 2 years of life. The mild form has recurrent infections from childhood.
7. SignsPeripheral blood neutrophilia (5,000~20,000/μL without infection, >100,000/μL with infection). No pus at sites of infection (sterile abscesses). Flow cytometry: markedly reduced surface CD18 and CD11a/b/c on neutrophils and lymphocytes. Persistent umbilical granuloma.
8. ScreeningIn infants with delayed cord separation + recurrent bacterial infections, CBC (to check the neutrophil count) → measurement of neutrophil CD18 and CD11b expression by flow cytometry. Newborns with a family history: flow cytometry immediately after birth. Prenatal: ITGB2 gene analysis after chorionic villus sampling or amniocentesis.
9. DiagnosisFlow cytometry (CD18/CD11a/CD11b expression): the key to confirmation. ITGB2 gene sequencing (including panel NGS). Neutrophil function tests (adhesion, chemotaxis, bactericidal capacity). Differential: idiopathic neutrophilia, other primary immunodeficiencies.
10. TreatmentSevere: hematopoietic stem cell transplantation (HSCT) is curative. Success rate with matched donors ~80%. Prophylactic antimicrobials (TMP-SMX, fluconazole). 2024 lentiviral gene therapy (marne-cel) phase 1 trial with 100% survival. G-CSF temporarily increases neutrophil counts.
11. PrognosisSevere (CD18<1%): most die in early childhood without treatment. Long-term survival possible after HSCT. Mild (CD18 11~30%): survival into adulthood possible, but quality of life reduced by recurrent infections and periodontitis. Early diagnosis and HSCT determine prognosis.
12. PreventionGenetic counseling, carrier testing, prenatal genetic diagnosis. Prophylactic antibiotics after early confirmation. Live vaccines contraindicated. Oral hygiene management (prevention of periodontitis). Early HSCT recommended for newborns with a family history.
13. ReferencesKishimoto TK et al. Leukocyte adhesion deficiency: Biochemical and genetic analysis of the CD18 deficiency … and 9 other papers

1. History

The history of Leukocyte Adhesion Deficiency type 1 (LAD-1) dates back to the late 1970s. At that time, several clinical reports began to draw attention to infant patients who suffered recurrent, life-threatening bacterial infections yet formed no pus at sites of infection and had markedly increased blood neutrophil counts. In particular, in 1979 Crowley and colleagues described children with this phenotype and proposed a functional abnormality in which neutrophils cannot migrate out of the blood vessels during infection.

In 1980, Anderson, Springer, et al. first confirmed by flow cytometry that a specific glycoprotein complex on the leukocyte surface was deficient in this patient group. These glycoproteins were later found to be the β2 integrin family composed of CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), and CD11c/CD18 (p150,95), and it was established that deficiency of CD18, the common β subunit, abolishes surface expression of all three complexes. Springer et al. gave the disease the name "Leukocyte Adhesion Deficiency" and identified the gene encoding CD18 (ITGB2, 21q22.3) as the causative gene (PMID: 6163695).

In 1987, Kishimoto et al. cloned the ITGB2 gene and reported various pathogenic variants, establishing the molecular genetic basis of LAD-1. Then in the 1990s, the fact that clinical severity varies with the expression level of the CD18 protein (expression <1% severe, 1~10% moderate, 11~30% mild) was established and began to be used for predicting prognosis. In the 2000s, LAD-2 (fucosylation defect) and LAD-3 (Kindlin-3 defect), which show similar clinical pictures but have different mechanisms, were additionally described, and LAD came to be classified as a heterogeneous group of diseases.

On the treatment side, hematopoietic stem cell transplantation (HSCT) has been established as the only curative therapy since the 1990s, and results have accumulated showing that the success rate of matched-donor transplantation reaches about 80%. In 2024, the groundbreaking results of a phase 1~2 multinational open-label clinical trial of autologous hematopoietic stem cell gene therapy using a lentiviral vector (marnetegragene-autotemcel, marne-cel)—all 9 patients surviving and HSCT unnecessary—were published, raising expectations of a shift in the treatment paradigm (PMID: 39226167). In Korea, it is included among diseases eligible for Special Copayment Reduction (V111) as one of the rare primary immunodeficiencies, and successful HSCT cases have been reported at immunodeficiency clinics of some university hospitals.


2. Causes

The cause of LAD-1 is pathogenic variants of the ITGB2 gene located on the long arm of chromosome 21 (21q22.3). The ITGB2 gene encodes the β2 integrin (integrin β2) subunit, that is, the CD18 protein. CD18 does not exist alone on the cell surface but forms heterodimers by noncovalent association with the α subunits CD11a (αL), CD11b (αM), and CD11c (αX), respectively. The three β2 integrin complexes formed in this way are LFA-1 (αLβ2, CD11a/CD18), Mac-1 (αMβ2, CD11b/CD18), and p150,95 (αXβ2, CD11c/CD18), which are expressed on the leukocyte surface and play key roles in immune and inflammatory responses.

When a pathogenic variant arises in the ITGB2 gene, the CD18 protein is not synthesized normally, or if synthesized, is produced in an unstable or nonfunctional form. Without CD18, complex formation with the α subunits is impossible, so none of the three β2 integrins can be expressed on the cell surface. As a result, expression of β2 integrins including LFA-1 is markedly reduced or lost on all leukocytes, including neutrophils, monocytes, and lymphocytes. More than 200 pathogenic ITGB2 variants have been reported to date, and various forms have been identified, including point mutations (missense/nonsense), frameshift variants, and splicing variants.

Functionally, LFA-1 (CD11a/CD18) binds ICAM-1 (CD54) and ICAM-2 (CD102) on the surface of vascular endothelial cells and is essential for neutrophils to adhere firmly to the vessel wall and migrate into tissues. LFA-1 is also involved in T-cell activation, immunological synapse formation, and killing of target cells by cytotoxic T cells, so its deficiency has broad effects not only on innate immunity but also on adaptive immune function. Mac-1, as a complement receptor (CR3), serves to phagocytose particles opsonized by bacterial iC3b, so loss of this function also aggravates susceptibility to bacterial infection.

The mode of inheritance is autosomal recessive, and both parents are clinically asymptomatic carriers of heterozygous ITGB2 variants. The incidence tends to increase in populations with high rates of consanguineous marriage. The residual expression level of the CD18 protein is the main factor determining clinical severity: expression below 1% of normal is classified as severe, 1~10% as moderate, and 11~30% as moderate to mild. Severe patients often die of infection before age 2 without treatment, but mild patients may survive into adulthood.


3. Genetics

LAD-1 follows an autosomal recessive mode of inheritance, and the causative gene is ITGB2 (integrin subunit beta 2, chromosome 21, 21q22.3). The OMIM entry number is #116920. The ITGB2 gene spans about 40 kilobases (kb) and consists of 16 exons, encoding the CD18 protein of 769 amino acids. The CD18 protein consists of an N-terminal ligand-binding domain, a beta-propeller structure, and a transmembrane domain, and is stably expressed on the cell surface through noncovalent association with the α subunit.

More than 200 pathogenic variants have been reported to date, and their spectrum is very broad. The most common variant types are as follows: first, missense variants, of which those altering conserved cysteine residues in the CD18 protein cause abnormal protein folding. Second, nonsense and frameshift variants, which create premature stop codons and result in truncated, nonfunctional proteins. Third, splicing variants, which produce abnormal mRNA through exon skipping or intron retention. Variants that maintain a small amount of CD18 expression (1~30%) are associated with mild phenotypes.

The clinical significance of genetic diagnosis is very great. Identification of the ITGB2 variant type is used for predicting clinical severity, genetic counseling, carrier testing, and prenatal diagnosis. The recurrence risk for heterozygous carrier parents is 25%, and fetal ITGB2 variants can be identified before birth through chorionic villus sampling (11~13 weeks of gestation) or amniocentesis (16~20 weeks of gestation). Recently, whole-exome sequencing (WES) and primary immunodeficiency panel NGS have become standard diagnostic methods, and the ACMG/AMP pathogenic variant classification criteria are applied to variant interpretation.

From a gene therapy perspective, ITGB2 is relatively small and easy to load into lentiviral vectors. The lentiviral gene therapy (marne-cel) reported in 2024 involves transducing the patient's own CD34+ hematopoietic stem cells ex vivo with a self-inactivating (SIN) lentiviral vector carrying normal ITGB2 cDNA and then reinfusing them; restoration of CD18 expression and prevention of infection were confirmed in all 9 patients, and it received FDA Breakthrough Therapy designation (PMID: 39226167).


4. General epidemiology

LAD-1 is an ultra-rare primary immunodeficiency with a worldwide prevalence of about 1/10 million, and fewer than 400 cases have been reported worldwide from the 1980s to the present. There is no sex difference, and it occurs equally in males and females. Regionally, a higher incidence has been reported in the Middle East, South Asia, and North Africa, where consanguineous marriage is relatively common, and a multicenter study in Turkey also identified a considerable number of cases in consanguineous families.

Regarding the distribution of clinical severity, about 75% of reported cases are the severe form with CD18 expression below 1%, and the remaining 25% are moderate to mild forms. The severe form tends to be first suspected in the neonatal period or early infancy from delayed cord separation or omphalitis and then diagnosed early as fatal bacterial infections recur. Without treatment, most die before 2 years of age, so there are almost no data on adult patients. In contrast, the mild form may present in childhood with recurrent infections, periodontitis, stomatitis, and the like, and is sometimes diagnosed at school age or in adolescence.

In Korea, no large-scale epidemiological survey has been published, but according to data from the Korea Rare Disease Foundation and the Health Insurance Review & Assessment Service (HIRA), the group of phagocyte defect disorders including LAD is known to be very rare among all primary immunodeficiencies. In Korea, cases have been reported sporadically at pediatric immunology clinics of university hospitals, and some successful hematopoietic stem cell transplantation cases have been confirmed. For patients registered under Special Copayment Reduction V111, the National Health Insurance coverage rate reaches 90%, providing financial support.

The similar disorders LAD-2 (OMIM #266265, SLC35C1 gene variants, fucosylation defect) and LAD-3 (OMIM #612840, FERMT3 gene variants, Kindlin-3 defect) are even rarer than LAD-1, with only dozens of cases reported worldwide. In LAD-2, leukocyte rolling is impaired due to defective expression of fucosylated ligands (sialyl-Lewis X, etc.), whereas LAD-3 is characterized by a defect in integrin inside-out signaling. ICD-10 D84.0 is the classification code that directly designates LFA-1 deficiency (LAD-1).


5. Pathophysiology

The pathogenesis of LAD-1 can be summarized as a stepwise breakdown of leukocyte extravasation mediated by β2 integrins. Normally, when an inflammatory response begins, vascular endothelial cells are activated by IL-1β, TNF-α, and others to express E-selectin, ICAM-1, and others on their surface, and neutrophils in the bloodstream gather at the site of infection through the steps of selectin-mediated rolling → chemokine receptor activation → high-affinity conversion of β2 integrins (LFA-1, Mac-1) by inside-out signaling → firm adhesion to ICAM-1 → transmigration across the endothelium → chemotactic migration within the tissue.

In LAD-1, when CD18 is deficient or loses function due to ITGB2 variants, surface expression of LFA-1 and Mac-1 itself is lost. As a result, β2 integrin-mediated firm adhesion does not occur, and even when stimulated by chemokines, neutrophils cannot adhere sufficiently to vascular endothelial cells and simply pass through the bloodstream. For this reason, neutrophils cannot reach sites of infection, and the primary defense functions of neutrophils, such as chemotaxis, phagocytosis, and the oxidative burst, are not exerted at all. This is why, clinically, infection sites show "sterile abscesses" or "ulcers without pus."

Meanwhile, in the peripheral blood, neutrophils that cannot migrate into tissues accumulate, producing marked neutrophilia. Even at baseline it is 5,000~20,000/μL, and during infectious episodes it commonly exceeds 100,000/μL. This paradoxical blood neutrophilia is an important clinical clue for suspecting LAD-1. Deficiency of Mac-1 (CR3, complement receptor 3) impairs phagocytosis of bacteria opsonized with iC3b, further reducing the efficiency of bacterial clearance. Deficiency of LFA-1 interferes with formation of the immunological synapse between T cells and antigen-presenting cells, partly impairing adaptive immune responses as well.

In addition, because LFA-1 is also involved in neutrophil degranulation and cytokine secretion, its deficiency causes multilayered functional abnormalities throughout the innate immune response. Because neutrophil infiltration of tissue is essential in the wound healing process after tissue injury, wound healing is severely delayed in LAD-1 patients. Delayed umbilical cord separation is a product of this mechanism, because normal cord separation requires neutrophil-mediated tissue remodeling.


6. Symptoms

The most characteristic and earliest symptom of LAD-1 is delayed umbilical cord separation. In normal newborns, the umbilical cord separates spontaneously within 7~14 days after birth, but in children with severe LAD-1 it does not separate for 28 days or more, in some cases even after several months, and omphalitis occurs repeatedly at the umbilical site. An umbilical granuloma may persist or ulceration of the periumbilical tissue may appear. This finding is the most important clinical clue for suspecting LAD-1 early.

Subsequently, recurrent bacterial and fungal infections begin within the first few months of life. The skin and mucous membranes are the main sites of infection, and Staphylococcus aureus and gram-negative enteric bacteria (E. coli, Klebsiella, Pseudomonas, etc.) are the main causative organisms. The characteristic finding of the infections is that typical pus does not form at inflamed sites, because neutrophils cannot reach the sites of infection. Skin ulcers have indistinct borders and heal very slowly, tending to recur even after surgical debridement.

Among oral complications, severe periodontitis appears from early childhood and often leads to premature tooth loss. Stomatitis and oral ulcers also recur. Gastrointestinal infections such as peritonitis and enteritis may occur, and pulmonary infections (pneumonia, lung abscess) are major life-threatening complications. In relatively mild patients (CD18 11~30%), these symptoms appear later or are less severe, but they still experience recurrent infections requiring regular antibiotic treatment. Fever, weight loss, and failure to thrive may also accompany them.

In patients with the severe form (CD18 <1%), most die of sepsis, pneumonia, or other serious infections within the first 1~2 years of life without treatment. In the mild form, survival is longer, beyond school age, but quality of life is reduced by recurrent periodontitis, oral ulcers, skin infections, and the like. Rarely, in the mild form, diagnosis is delayed until adulthood. Because T-lymphocyte function is impaired, cell-mediated immune responses are also reduced, and in some patients viral (herpesviruses, etc.) or fungal (Candida) infections are also frequent.


7. Signs

The most prominent sign on physical examination and laboratory testing is peripheral blood neutrophilia. Even at baseline without infection, the blood absolute neutrophil count (ANC) reaches 5,000~20,000/μL, and during acute infectious episodes it rises markedly to 50,000~100,000/μL or higher. This is because neutrophils that cannot migrate into tissues accumulate in the peripheral blood, and the paradoxical finding of leukocytosis without pus at sites of infection is characteristic.

Skin findings include pus-free ulcers at sites of infection, without abscess formation unlike ordinary bacterial infections. At the umbilical site, an unseparated umbilical cord remnant or umbilical granuloma may be observed. In the oral cavity, gingivitis and periodontitis are severe, with red, swollen gingiva that bleed easily but little purulent exudate. In patients beyond childhood, premature tooth loss is a characteristic finding.

Flow cytometry is the key diagnostic test, measuring surface expression on peripheral blood neutrophils (or monocytes, lymphocytes) using anti-CD18, anti-CD11a, and anti-CD11b antibodies. In the severe form, CD18, CD11a, and CD11b expression is less than 1% of normal controls and almost undetectable, while in the mild form it is reduced to the 1~30% level. Immunoglobulin levels are usually normal or even elevated due to infectious responses, which helps differentiate it from humoral immunodeficiency.

Neutrophil function tests include the neutrophil adhesion assay, chemotaxis testing, and the oxidative burst test after phagocytosis. In LAD-1, adhesion and chemotaxis are markedly reduced, but intracellular bactericidal capacity (oxidative burst) is often relatively preserved, which is used to differentiate it from chronic granulomatous disease (CGD). In combined infections, inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin rise markedly.


8. Screening

LAD-1 is not currently included in routine newborn population screening panels, but when there is clinical suspicion, it is very important to begin screening early. The key clues for clinical screening are as follows: (1) delayed umbilical cord separation in the newborn (more than 28 days), (2) recurrent omphalitis or persistent umbilical granuloma in the neonatal period, (3) recurrent bacterial infections without pus at sites of infection, (4) marked leukocytosis during infection (>30,000/μL). If even one of these applies, testing including flow cytometry should proceed immediately.

As an initial screening test, the complete blood count with differential (CBC with differential) is the easiest. In LAD-1, the ANC is elevated even at baseline and increases even more markedly with infection, so when unexplained neutrophilia persists on CBC, β2 integrin expression testing is needed. In newborns with a family history (when a sibling has been diagnosed with LAD-1), CD18 expression can be checked by flow cytometry on cord blood or peripheral blood immediately after birth.

In high-risk families (when a parent has been identified as a carrier of an ITGB2 variant), prenatal diagnosis is possible. ITGB2 gene variants are analyzed in fetal cells obtained by chorionic villus sampling (CVS) at 11~13 weeks of gestation or amniocentesis at 16~20 weeks of gestation. When in vitro fertilization is planned, preimplantation genetic testing (PGT) is also an option. With respect to newborn screening, it should be noted that TREC (T cell receptor excision circle)-based immunodeficiency screening mainly detects T-cell deficiency disorders, and LAD-1 is not detected by this method because TREC levels are normal.


9. Diagnosis

LAD-1 is confirmed mainly by measuring leukocyte surface CD18 and CD11a/CD11b expression by flow cytometry. Using anti-CD18 monoclonal antibodies (e.g., clone MHM23 or TS1/18) and anti-CD11b monoclonal antibodies, the mean fluorescence intensity (MFI) is measured in peripheral whole blood or isolated leukocytes. In severe LAD-1, expression is close to 0, and in mild to moderate forms it is reduced to 1~30% of normal. This test can be performed relatively simply and quickly and is used as the first confirmatory step in diagnosis.

For genetic testing, ITGB2 gene sequencing is the standard. Pathogenic variants are identified using Sanger sequencing, a next-generation sequencing (NGS)-based primary immunodeficiency gene panel, or whole-exome sequencing (WES). Variants are classified as Pathogenic/Likely pathogenic according to the ACMG/AMP guidelines. In addition to confirmation, genetic analysis is essential for genetic counseling, carrier testing, and prenatal diagnosis.

Neutrophil function tests include in vitro adhesion assays (measurement of adhesion to glass or endothelial cell surfaces), chemotaxis assays (under-agarose or Boyden chamber methods), and oxidative burst tests after phagocytosis (DHR or NBT methods). Adhesion and chemotaxis are markedly reduced in LAD-1, while the oxidative burst is relatively preserved, which is a point of differentiation from chronic granulomatous disease (CGD). Other tests such as serum immunoglobulins (IgG/A/M/E), lymphocyte proliferation responses (PHA, ConA stimulation), and complement levels (C3, C4) are also measured for differential diagnosis.

Diseases to consider in the clinical differential diagnosis include chronic granulomatous disease (CGD, variants in CYBB/NCF1/NCF2, etc.), LAD-2 (SLC35C1 variants, accompanied by Bombay blood group phenotype), LAD-3 (FERMT3 variants, accompanied by a bleeding tendency resembling Glanzmann thrombasthenia), and severe congenital neutropenia (Kostmann syndrome, ELANE/HAX1 variants). In particular, CGD shows abscess formation at sites of infection and abnormal oxidative burst test results, whereas LAD-1 has no abscesses and a normal oxidative burst, which helps differentiation.


10. Treatment

The only curative therapy for LAD-1 is allogeneic hematopoietic stem cell transplantation (allogeneic HSCT). In patients with the severe form (CD18 <1%), HSCT should be performed as early as possible (before the first serious infection or as soon as possible after the first infection). The success rate of HLA-matched sibling donor (MSD) transplantation is about 80%, and HLA-matched unrelated donor (MUD) transplantation shows a similar success rate. Haploidentical transplantation has a lower success rate of about 50% but is performed as an alternative when no suitable donor is available. After successful transplantation, when CD18 expression normalizes and neutrophil function recovers, the risk of recurrent infection decreases markedly.

As prophylactic treatment until HSCT is performed, bacterial prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX), fungal prophylaxis with fluconazole or itraconazole, and herpesvirus prophylaxis with acyclovir are recommended. During acute infectious episodes, broad-spectrum antibiotics are actively administered and adjusted according to bacterial culture results as needed. Granulocyte transfusion may be considered as a temporary defense in life-threatening infections, but because of the risks of alloimmune reactions and infection transmission, which may affect HSCT donor selection, it should be used cautiously. G-CSF (granulocyte colony-stimulating factor) can further increase peripheral blood neutrophil counts but does not improve the ability to migrate into tissues itself, so its use is limited.

The lentiviral gene therapy (marnetegragene-autotemcel, marne-cel) published in 2024 involves transducing the patient's own CD34+ hematopoietic stem cells ex vivo with a self-inactivating (SIN) lentiviral vector carrying normal ITGB2 cDNA and reinfusing them after myelosuppressive conditioning. In a phase 1~2 multinational open-label clinical trial (NCT03812263), 1-year survival of all 9 patients, restoration of CD18 expression, and prevention of serious infections were confirmed (PMID: 39226167). This treatment has the advantage of not requiring a donor and thus carrying no risk of graft-versus-host disease (GVHD), and it has received FDA Breakthrough Therapy designation and is under review for approval.

Dental care is also an important component of treatment. Periodontitis and gingivitis are managed with active dental treatment (professional scaling, periodontal surgery), antimicrobial mouthwash (chlorhexidine), topical antibiotics, and similar measures. Live vaccines (BCG, varicella, measles-mumps-rubella combination, etc.) are absolutely contraindicated, and inactivated vaccines are given according to the standard immunization schedule.


11. Prognosis

The prognosis of LAD-1 is determined by the level of residual CD18 expression and whether and when HSCT is performed. When patients with the severe form (CD18 <1%) go untreated, most die of sepsis, pneumonia, or another fatal infection within the first 2 years of life. In past reports, the majority of untreated patients with the severe form died before age 2.

Prognosis improves markedly when HSCT is performed early. In HLA-matched sibling transplantation, a 5-year survival rate of about 80% has been reported, and when CD18 expression recovers sufficiently after successful transplantation, the rate of recurrent infection falls substantially and normal growth and development become possible. Transplant-related complications include graft-versus-host disease (GVHD), graft failure, infection, and organ damage related to toxic conditioning. Haploidentical transplantation has a lower success rate with a higher risk of GVHD, and retransplantation is required if the graft fails.

Patients with the mild form (CD18 11–30%) have reduced quality of life due to recurrent infections and periodontitis but can survive into adulthood. However, organ damage may develop as serious infectious episodes accumulate, or early death may occur from an unexpected fatal infection. The 2024 gene therapy clinical trial results (100% survival at 1 year) raise great hopes for improved prognosis in the future, but long-term follow-up data are still accumulating. Overall, early diagnosis and early HSCT or gene therapy are the most decisive factors in determining prognosis.


12. Prevention

For primary prevention (preventing occurrence), genetic counseling and carrier testing are key. When the siblings or parents of a patient with LAD-1 are identified as carriers, the recurrence risk (25%) is communicated through preconception genetic counseling, and preimplantation genetic testing (PGT-M) can be performed during an in vitro fertilization (IVF) cycle so that only unaffected or carrier embryos are transferred. If a pregnancy is already under way, prenatal diagnosis is possible by fetal ITGB2 variant analysis through chorionic villus sampling or amniocentesis.

For secondary prevention (early diagnosis and prevention of complications), it is important to achieve early diagnosis by performing an immunodeficiency evaluation (CBC, flow cytometry) immediately when delayed umbilical cord separation is observed in the neonatal period. After confirmation, measures include prophylactic antimicrobials (TMP-SMX, antifungals), strict avoidance of live vaccines, dental hygiene care, and referral for early HSCT or gene therapy. Caregivers should be educated and advised to visit a medical facility immediately for warning signs such as fever, skin ulcers, and recurrent oral ulcers.

Tertiary prevention (minimizing complications) includes follow-up of immune function after HSCT (regular flow cytometry, infection markers), management of periodontitis, re-establishment of immunization (timely revaccination with inactivated vaccines after transplantation), and long-term follow-up. Psychosocial support for patients and caregivers during treatment is also needed, and active use of the Korean rare disease support system (Special Copayment Reduction V111, medical expense support programs) is recommended to improve treatment adherence.


13. References

  1. Kishimoto TK, Hollander N, Roberts TM, Anderson DC, Springer TA. Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. Cell. 1987;50(2):193-202. PMID: 3594570
  2. Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med. 1987;38:175-194. PMID: 3555290
  3. Etzioni A. Leukocyte adhesion deficiency (LAD) syndromes. Orphanet J Rare Dis. 2010;5:48. PMID: 21162739
  4. van de Vijver E, van den Berg TK, Kuijpers TW. Leukocyte adhesion deficiencies. Hematol Oncol Clin North Am. 2013;27(1):101-116. PMID: 23351992
  5. Moutsopoulos NM, Konkel JE. Tissue-Specific Immunity at the Oral Mucosal Barrier. Trends Immunol. 2018;39(4):276-287. PMID: 29452978
  6. Dinauer MC. Disorders of Neutrophil Function: An Overview. Methods Mol Biol. 2014;1124:501-515. PMID: 24504961
  7. Kansouri H, et al. Novel ITGB2 Mutation Is Responsible for a Severe Form of Leucocyte Adhesion Deficiency Type 1. Front Immunol. 2022;13:818882. PMID: 35280996
  8. Gennery AR. Hematopoietic stem cell transplantation in primary immunodeficiencies beyond SCID. Hematology Am Soc Hematol Educ Program. 2017;2017:383-389. PMID: 29222283
  9. Gomez-Almaguer D, et al. Clinical and laboratory findings in patients with leukocyte adhesion deficiency type I: A multicenter study in Turkey. Pediatr Allergy Immunol. 2021;32(6):1342-1348. PMID: 33759241
  10. Kohn DB, et al. Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1. N Engl J Med. 2024;390(20):1862-1871. PMID: 39226167